S0820, Adenoma and Second Primary Prevention Trial
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Research Base: SWOG Cancer Research Network
NCT ID: NCT01349881
NCI Protocol Number: SWOG-S0820
Status: Active, not recruiting
For more information see ClinicalTrials.gov
Interventions
- Eflornithine placebo & sulindac placebo
- eflornithine & sulindac placebo
- Eflornithine placebo & sulindac
- Eflornithine plus sulindac
Condition
Colorectal Neoplasms
Trial Type
Cancer Prevention
See a list of participating sites on ClinicalTrials.gov